Pathogen-reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange.

Fiche publication

Date publication

janvier 2026

Journal

Transfusion

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MANGIN Pierre

Tous les auteurs :
Tupin F, Mouriaux C, Hechler B, Kaastrup K, Yegneswaran S, Corash L, Mangin PH

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41618717

Résumé

Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto-immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion-transmitted infection (TTI). Amotosalen-UVA Pathogen Reduction technology is FDA approved to manufacture pathogen-reduced plasma, cryoprecipitate reduced (PRPCR), a form of cryoprecipitate poor plasma (CPP) with potentially improved TPE outcomes and reduced TTI risk.